Among patients with pulmonary arterial hypertension treated with 72-week seralutinib, those deemed responders had more improved measures, according to a poster presented at the Pulmonary Vascular ...

Gossamer Bio's Seralutinib shows promise for PAH and PH-ILD treatment. The main event comes with its topline results in Q4 ...

Safety of a Potential New Treatment to Manage Complications from Sickle Cell Disease Apr. 11, 2024 — A drug approved to treat pulmonary arterial hypertension may be effective at managing ...

Advanced therapies, medicines bring new hope for pulmonary hypertension patients: Dr Manisha Mendiratta: Shardul Nautiyal, Mumbai Saturday, February 8, 2025, 08:00 Hrs [IST] Dr Ma ...

Seropositive rheumatoid arthritis may be protective against the development of PAH, based on results of Mendelian randomization analyses.

Women are more likely to have pulmonary arterial hypertension, but men tend to have worse outcomes and worse treatment responses.

Sildenafil was effective for reducing diastolic dysfunction and altered ejection fraction among patients with SSc.